Hepatitis C virus infection and nonalcoholic steatohepatitis.
- 1 May 2012
- journal article
- Vol. 8 (5) , 305-12
Abstract
Nonalcoholic fatty-liver disease (NAFLD) is one of the most prevalent liver diseases in the Western hemisphere. The rising rates of obesity and diabetes mellitus correlate with the increasing incidence of NAFLD, which is the hepatic manifestation of metabolic syndrome. Hepatitis C virus infection is another common cause of liver disease worldwide. Up to 70% of patients with chronic hepatitis C (CHC) will have concomitant steatosis. The presence of NAFLD has been implicated as a cause of lower viral response rates in CHC patients who are treated with pegylated interferon and ribavirin. This review will focus on the factors that lead to NAFLD in the setting of hepatitis C virus infection, including viral and host factors-in particular, inflammatory mediators, cytokines, and lipid peroxidation. This paper will also discuss the implications of NAFLD and nonalcoholic steatohepatitis regarding fibrosis progression, risk of hepatocellular carcinoma, and limitations with antiviral therapy.Keywords
This publication has 87 references indexed in Scilit:
- The role of fatty acids in the development and progression of nonalcoholic fatty liver diseaseThe Journal of Nutritional Biochemistry, 2008
- The lysosomal-mitochondrial axis in free fatty acid–induced hepatic lipotoxicityHepatology, 2007
- Benefits of lifestyle modification in NAFLDGut, 2007
- Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative StressJournal of Virology, 2007
- Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesisProceedings of the National Academy of Sciences, 2007
- The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patientsJournal of Hepatology, 2004
- Fibrosis progression in chronic hepatitis C virus infectionGut, 2004
- Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis CHepatology, 2003
- Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionCancer, 2003
- Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy?Journal of Hepatology, 2001